Citation Impact
Citing Papers
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
2015
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
Cancer Statistics, 2021
2021 Standout
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
2015
Distinct MutS DNA-binding Modes That Are Differentially Modulated by ATP Binding and Hydrolysis
2001 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
2009
Cisplatin: From DNA damage to cancer chemotherapy
2001
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
2004 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma
2003
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
2008 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The Immunopathophysiology of Endometriosis
2018
The biology and management of non-small cell lung cancer
2018 StandoutNature
Differential and Simultaneous Adenosine Di- and Triphosphate Binding by MutS
2003 StandoutNobel
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Hydrolytically Deficient MutS E694A Is Defective in the MutL-dependent Activation of MutH and in the Mismatch-dependent Assembly of the MutS · MutL · Heteroduplex Complex
2003 StandoutNobel
Lung Cancer
2008 Standout
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
2004
DNA mismatch repair: MutS structures bound to mismatches
2001
Head and neck cancer
2008 Standout
The MET axis as a therapeutic target
2009
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel–Dreyer chromatography
2003
Assembly and Molecular Activities of the MutS Tetramer
2003 StandoutNobel
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells
2004
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
1998
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
The roles of copper transporters in cisplatin resistance
2007
Cellular processing of platinum anticancer drugs
2005 Standout
Requirement for ERK Activation in Cisplatin-induced Apoptosis
2000
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 Standout
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines
1998
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
1996
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Autophagy and Aging
2011 Standout
Estrogen plus Progestin and the Risk of Coronary Heart Disease
2003 Standout
Transcriptional Regulation of the Human Transferrin Gene by Gadd153 in Hepatoma Cells
2003
Differential Specificities and Simultaneous Occupancy of Human MutSα Nucleotide Binding Sites
2004 StandoutNobel
How Chemoproteomics Can Enable Drug Discovery and Development
2012
Laryngeal preservation in head and neck cancer: multidisciplinary approach
2006
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
The synthetic challenge of diazonamide A, a macrocyclic indole bis-oxazole marine natural product
2008
The Hallmarks of Aging
2013 Standout
The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure
2004
Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts
1995
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Recent insights into platinum drug resistance in cancer
1998
Clinical Perspectives on Platinum Resistance
2000
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
Head and Neck Cancer
2001 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake
2000
Atroposelective Total Synthesis of Axially Chiral Biaryl Natural Products
2010 Standout
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
2000
Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer
2017
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
2004 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Receptor‐mediated tobacco toxicity: cooperation of the Ras/Raf‐1/MEK1/ERK and JAK‐2/STAT‐3 pathways downstream of a7 nicotinic receptor in oral keratinocytes
2006
Head and Neck Cancer
2020 Standout
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
2006
The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats
2003
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal
1996
Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium The GenBank accession numbers for the sequences reported in this paper are AF233610 (S-1-P lyase), AF233612 (PIP5K), AF233611 (P2Y purine receptor 1), AF233613 (CAAX prenyl protease) and AF233614 (unidentified gene).
2000
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
INTRAPERITONEAL CHEMOTHERAPY
1994
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines
2006
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Epidermal Growth Factor Receptor Family and Chemosensitization
1997
Non-invasive, real-time reporting drug release in vitro and in vivo
2015
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Chemistry and Biology of Diazonamide A: Second Total Synthesis and Biological Investigations
2004
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
1999
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
2016
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin
2000
Inhibitors of the anaplastic lymphoma kinase
2012
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Endometriosis
2020 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Palladium‐Catalyzed, tert‐Butyllithium‐Mediated Dimerization of Aryl Halides and Its Application in the Atropselective Total Synthesis of Mastigophorene A
2016 StandoutNobel
Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
2011
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
2002
Anaplastic lymphoma kinase: signalling in development and disease
2009
Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study
2002
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up
2003
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer
2008
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
2008
Chemical Glycoproteomics
2016 StandoutNobel
Works of Gerrit Los being referenced
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
2007
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2010
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
2007
Enhancement of drug sensitivity of human malignancies by epidermal growth factor
1995
Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action
1991
Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin
2003
Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin
1994
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo
1994
The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat
1990
Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatment
1990
Signaling and drug sensitivity
1994
Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells
1996
Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA
1993
Experimental and clinical status of intraperitoneal chemotherapy
1990
Non-invasive measurement of chemotherapy drug concentrations in tissue: preliminary demonstrations ofin vivomeasurements
1999
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
2014
A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel
1999
Loss of DNA Mismatch Repair: Effects on the Rate of Mutation to Drug Resistance
1997
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer.
1994
A Novel Organ Preservation Protocol for Advanced Carcinoma of the Larynx and Pharynx
1996
Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats
1991
Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts
1999
Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents
2001
Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy
1991
Identification of genes differentially expressed in cisplatin-sensitive versus resistant tumour cells
1999
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
1992
Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.
1994
Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
2005
Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy.
1989
Platinum resistance: Laboratory findings and clinical implications
1993
A Phase 1 Study of ANB020, an anti-IL-33 monoclonal Antibody in Healthy Volunteers
2017
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance
2004
Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.
1989
Prediction‐based threading of the hMSH2 DNA mismatch repair protein
1998
Platinum Resistance: Experimental and Clinical Status
1994